Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts


DOP81: Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studiesECCO'22
Year: 2022
Authors: Verstockt, B.(1);Al Mahi, N.(2);Pivorunas, V.(3);Smaoui, N.(2);Guay, H.(3);Kennedy, N.A.(4);Hanauer, S.B.(5);Ferrante, M.(1);Panés, J.(6);Vermeire, S.(1);
(1)University Hospital Leuven & KU Leuven, Gastroenterology, Leuven, Belgium;(2)AbbVie Inc., Immunology, North Chicago, United States;(3)AbbVie Bioresearch Centre, Immunology, Worcester, United States;(4)Royal Devon and Exeter NHS Foundation Trust, Gastrointestinal and Liver Service, Exeter, United Kingdom;(5)Northwestern University Feinberg School of Medicine, Department of Medicine, Evanston, United States;(6)IDIBAPS- CIBERehd, Hospital Clinic de Barcelona, Barcelona, Spain;
DOP82: Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumabECCO'22
Year: 2022
Authors: Schreiber, S.W.(1);Cross, R.(2);Panaccione, R.(3);D'Haens, G.(4);Bossuyt, P.(5);Colombel, J.F.(6);Louis, E.(7);Dubinsky, M.(6);Kligys, K.(8);Neimark, E.(8);Song, A.(8);Zambrano, J.(8);Cheng, E.(8);Ferrante, M.(9);
(1)University Hospital Schleswig-Holstein, Department Internal Medicine I- Kiel University, Kiel, Germany;(2)University of Maryland School of Medicine, Department of Medicine, Baltimore, United States;(3)University of Calgary, Inflammatory Bowel Disease Unit, Calgary- Alberta, Canada;(4)Amsterdam University Medical Centers, Department of Inflammatory Bowel Diseases, Amsterdam, Netherlands Antilles;(5)Imelda General Hospital, Inflammatory Bowel Disease Clinic, Bonheiden, Belgium;(6)Icahn School of Medicine, Department of Gastroenterology, Mt. Sinai, United States;(7)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;(8)AbbVie Inc., Department of Gastroenterology, North Chicago, United States;(9)University Hospitals Leuven, KU Leuven, Leuven, Belgium;
DOP83: Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn’s Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studiesECCO'22
Year: 2022
Authors: Atreya, R.(1);Feagan, B.(2);Shchukina, O.(3);Jairath, V.(4);Rieder, F.(5);Hisamatsu, T.(6);Siegmund, B.(7);Rizzo, J.(8);Kligys, K.(8);Neimark, E.(8);Song, A.(8);Zambrano, J.(8);Mallick, M.(8);Cheng, E.(8);Armuzzi, A.(9);
(1)Friedrich-Alexander-University Erlangen-Nürnberg, Medicine, Erlangen, Germany;(2)Western University, Gastroenterology, London, Canada;(3)Pavlov First Saint Petersburg State Medical University, Gastroenterology, Saint Petersburg, Russian Federation;(4)Western University, Medicine, London, Canada;(5)Digestive Diseases and Surgery Institute- Cleveland Clinic, Gastroenterology- Hepatology and Nutrition, Cleveland, United States;(6)Kyorin University School of Medicine, Gastroenterology, Mitaka, Japan;(7)Charité – Universitätsmedizin Berlin, Department of Medicine Divisions of Gastroenterology- Infectious Diseases- Rheumatology, Berlin, Germany;(8)AbbVie Inc., Gastroenterology, North Chicago, United States;(9)Fondazione Policlinico Universitario A. Gemelli IRCCS, Gastroenterology, Rome, Italy;
DOP84: Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn’s Disease: Post-hoc analysis from the phase 3 study FORTIFYECCO'22
Year: 2022
Authors: Irving, P.M.(1);Abreu, M.(2);Axler, J.(3);Gao, X.(4);Torres, J.(5);Neimark, E.(6);Song, A.(7);Wallace, K.(7);Kligys, K.(8);Berg, S.(8);Liao, X.(7);Panaccione, R.(9);
(1)St. Thomas' Hospital, Department of Gastroenterology, London, United Kingdom;(2)University of Miami Miller School of Medicine, Crohn's & Colitis Center, Miami, United States;(3)TDDA, Toronto Digestive Disease Associates Inc, Vaughan, Canada;(4)The Sixth Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology- The Center for Inflammatory Bowel Disease, Guangzhou-, China;(5)Hospital Beatriz Ângelo, Division of Gastroenterology-, Loures, Portugal;(6)AbbVie, Clinical Development, Worcester, United States;(7)AbbVie, Clinical Development, North Chicago, United States;(8)AbbVie, Global Medical Affairs, Mettawa, United States;(9)Cumming School of Medicine- University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Canada;
DOP85: Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn’s Disease and inadequate response to risankizumab maintenance therapyECCO'22
Year: 2022
Authors: Baert, F.J.(1);Atreya, R.(2);Kakuta, Y.(3);Long, M.(4);Roblin, X.(5);Neimark, E.(6);Song, A.(6);Wallace, K.(6);Kingys, K.(6);Mallick, M.(6);Liao, X.(6);Lim, A.(7);
(1)AZ Delta, Department of Gastroenterology, Roeselare-Menen, Belgium;(2)Friedrich-Alexander-University Erlangen-Nürnberg- University Hospital Erlangen, Department of Medicine, Erlangen, Germany;(3)Tohoku University Graduate School of Medicine, Division of Gastroenterology, Seiryo- Aoba- Sendai, Japan;(4)University of North Carolina, Division of Gastroenterology and Hepatology- Multidisciplinary Center for Inflammatory Bowel Diseases, Chapel Hill, United States;(5)University Hospital of Saint-Étienne, Department of Gastroenterology, Saint-Étienne, France;(6)AbbVie Inc., Department of Gastroenterology, North Chicago, United States;(7)John Flynn Private Hospital, Department of Gastroenterology, Tugun- Queensland, Australia;
DOP86: Mirikizumab-induced upregulation of colonic transcripts correlates with improvements in stool frequency in a phase 2 study of patients with moderately to severely active Ulcerative ColitisECCO'22
Year: 2022
Authors: Steere, B.(1);Powell, N.(2);Higgs, R.(1);Wang, Y.C.(1);Milch, C.(1);Sandborn, W.J.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Krishnan, G.(1);
(1)Eli Lilly and Company, Biomedicines, Indianapolis, United States;(2)Imperial College London, Gastroenterology, London, United Kingdom;(3)University of California San Diego, Gastroenterology, San Diego, United States;(4)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(5)Medical University of Vienna, Internal Medicine, Vienna, Austria;(6)Amsterdam UMC, Gastroenterology, Amsterdam, The Netherlands;
DOP87: Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn’s DiseaseECCO'22
Year: 2022
Authors: Magro, F.(1);De Hertogh, G.(2);Protic, M.(3);Chan, L.S.(3);Pollack, P.(3);Feagan, B.G.(4);Harpaz, N.(5);Pai, R.(6);Reinisch, W.(7);
(1)University Hospital São João, Pharmacology, Porto, Portugal;(2)KU Leuven, University Hospitals Leuven, Leuven, Belgium;(3)Eli Lilly and Company, Biomedicines, Indianapolis, United States;(4)Robarts Clinical Trials Inc, Medicine- Epidemiology & Biostatistics, London, Canada;(5)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(6)The Mayo Clinic, Gastroenterology, Scottsdale, United States;(7)Medical University of Vienna, Internal Medicine, Vienna, Austria;
DOP88: Long-term real-world data of ustekinumab in Crohn’s Disease – the Stockholm ustekinumab study – STOCUSTEECCO'22
Year: 2022
Authors: Bello, F.(1);Lördal, M.(2);Johansson, F.(3);Sabhan, H.(4);Muhsen, S.(2);Borin, A.(5);Forsberg, O.(6);Wennerström, C.(6);Söderman, C.(4);Almer, S.(1);
(1)Karolinska University Hospital, IBD-Unit- Division of Gastroenterology, Stockholm, Sweden;(2)Danderyd Hospital, Divsion of Gastroenterology and Hepatology- Department of Medicine, Danderyd, Sweden;(3)Danderyd Hospital, Medical Library, Danderyd, Sweden;(4)S:t Göran’s Hospital, Gastroenterology Unit- Medical Department, Stockholm, Sweden;(5)South Hospital, Department of Medicine, Stockholm, Sweden;(6)Janssen Cilag AB, Immunology, Stockholm, Sweden;
DOP89: Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s DiseaseECCO'22
Year: 2022
Authors: Wang, Z.(1);Kantasiripitak, W.(1);Verstockt, B.(2,3);João, S.(2,3);Ferrante, M.(2,3);Declerck, P.(1);D’Haens, G.(4);Laharie, D.(5);Vermeire, S.(2,3);Dreesen, E.(1);
(1)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(4)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)Université de Bordeaux, Department of Hepato-gastroenterology and Digestive Oncology, Bordeaux, France;
DOP90: Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trialECCO'22
Year: 2022
Authors: Peyrin-Biroulet, L.(1);Vermeire, S.(2);D'Haens, G.R.(3);Panés, J.(4);Dignass, A.(5);Magro, F.(6,7);Le Bars, M.(8);Lahaye , M.(9);Nazar, M.(10);Ni, L.(11);Bravatà , I.(12);Lavie , F.(9);Daperno , M.(13);Lukáš , M.(14);Armuzzi , A.(15);Löwenberg , M.(3);Gaya , D.R.(16);Danese , S.(17); STARDUST
(1)University Hospital of Nancy- University of Lorraine- INSERM U1256 NGERE, Department of Hepato-Gastroenterology, Houdemont, France;(2)University Hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;(3)Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands;(4)Hospital Clinic of Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;(5)Agaplesion Markus Hospital, Department of Medicine I, Frankfurt/Main, Germany;(6)Institute for Molecular and Cell Biology- Faculty of Medicine University of Porto, Department of Pharmacology & Therapeutics, Porto, Portugal;(7)Hospital de São João, Department of Gastroenterology, Porto, Portugal;(8)Janssen-Cilag, Medical Affairs, Issy-les-Moulineaux, France;(9)Janssen-Cilag BV, Medical Affairs, Breda, The Netherlands;(10)Janssen-Cilag Polska Sp. z o.o, Medical Affairs, Warsaw, Poland;(11)Janssen-Cilag Russia, Medical Affairs, Moscow, Russian Federation;(12)Janssen-Cilag, Medical Affairs, Milan, Italy;(13)Mauriziano Hospital, Gastroenterology Unit, Turin, Italy;(14)Clinical Center ISCARE, Clinical and Research Center for Inflammatory Bowel Diseases, Prague, Czech Republic;(15)Fondazione Policlinico Universitario A. Gemelli IRCCS, IBD Unit- Università Cattolica del Sacro Cuore, Rome, Italy;(16)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(17)Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy;
N01: Type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with Inflammatory Bowel Disease: a multicentre, comparative study.ECCO'22
Year: 2022
Authors: De Dycker, E.(1);Hoefkens, E.(2);Asnong, K.(2);Geens, P.(1);Lembrechts, N.(2);Lambrechts, T.(1);Van de Schoot, I.(2);Paps, A.(2);Vermeire, S.(1);Pouillon, L.(2);Ferrante, M.(1);Bossuyt, P.(2);
(1)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Imelda General Hospital Bonheiden, Department of Gastroenterology, Bonheiden, Belgium;
N02: The importance of the multidisciplinary team (MDT) and its impact on quality of life and medication adherence in patients with Inflammatory Bowel DiseaseECCO'22
Year: 2022
Authors: Herrerias, G.(1);Barros, J.R.(2);Lopes, M.A.(1);Saad-Hossne, R.(3);Baima, J.P.(4);Sassaki, L.Y.(4);
(1)São Paulo State University Unesp- Medical School- Botucatu, medical clinic department, Botucatu, Brazil;(2)Federal University of Rio de Janeiro- Macae- Brazil, Nursing Institute, Macaé/RJ, Brazil;(3)São Paulo State University Unesp- Medical School- Botucatu/SP, Department of surgery and orthopedics, Botucatu/SP, Brazil;(4)São Paulo State University Unesp- Medical School- Botucatu/SP, Department of Clinical Medicine, Botucatu/SP, Brazil;
N03: Medication adherence in relation to Health-related Quality of Life in patients with Inflammatory Bowel Disease – a cross-sectional studyECCO'22
Year: 2022
Authors: Johansson, E.(1);Lovén WickmanRN- PhD, U.(2);
(1)Linköping university, Medical student- Department of Medical and Health Sciences, Linköping, Sweden;(2)Linnaeus University, Department of Health and Caring Sciences, Kalmar, Sweden;
N04: A systematic review of the impact of Inflammatory Bowel Disease (IBD) on family membersECCO'22
Year: 2022
Authors: Thapwong, P.(1);Norton, C.(1);Rowland, E.(1);Farah, N.(1); Czuber- Dochan, W.(1);
(1)King's college London, Nursing faculty, London, United Kingdom;
N05: Patient involvement in inflammatory bowel disease therapy and disease-related parameters - is there an association?ECCO'22
Year: 2022
Authors: Haj Natour, O.(1);Magnezi, R.(2);Ben Horin, S.(3);Lipkin, M.(3);Ungar, B.(3);Galper, A.(3);Sina, S.(3);Kopylov, U.(3);
(1)Tel-HaShomer Sheba Medical Center+ Bar Ilan University, Department of Gastroenterology, Ramat Gan, Israel;(2)Bar Ilan University, Department of Manegment, Ramat Gan, Israel;(3)Tel-HaShomer Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;
N06: Assessing stakeholder identified barriers and enablers to Ultrasound implementation for assessment of Crohn's Disease in the UK: A qualitative interview studyECCO'22
Year: 2022
Authors: RadfordBSc- MSc- PGCert- PhD student, S.(1);Leighton, P.(2);Coad, J.(3);Moran, G.(1);
(1)Nottingham NIHR Biomedical Research Centre, Liver and Gastrointestinal Disorders Translational Medicine, Nottingham, United Kingdom;(2)The University of Nottingham, Faculty of Medicine, Nottingham, United Kingdom;(3)University of Nottingham, Faculty of Health Sciences, Nottingham, United Kingdom;
N07: Current practices of Ultrasound for assessment of Crohn’s Disease in the UKECCO'22
Year: 2022
Authors: RadfordBSc- MSc- PGCert- PhD student, S.(1);Moran, G.(1);
(1)Nottingham NIHR Biomedical Research Centre, Inflammatory Bowel Disease, Nottingham, United Kingdom;Nottingham NIHR Biomedical Research Centre
N08: The influence of the Covid-19 epidemic on access to medical advice for children with Inflammatory Bowel Disease (IBD), based on patients from The Children's Memorial Health Institute, Warsaw (IPCZD).ECCO'22
Year: 2022
Authors: Kotkowicz Szczur, M.(1);Matuszczyk, M.(2);Kierkuś, J.(2);
(1)Instytut Pomnik Centrum Zdrowia Dziecka, Oddział Gastroenterologi- Hepatologii i Zaburzeń Karmienia, Warsaw, Poland;(2)The Children's Memorial Health Institute., Department of Gastroenterology- Hepatology- Feeding disorders and Pediatrics, Warsaw, Poland;
N09: Disease knowledge and quality of life perception in Inflammatory Bowel Disease: a randomised controlled trialECCO'22
Year: 2022
Authors: MartinatoRN PhD, M.(1);Comoretto, R.I.(2);Monaco, E.(1);Ocagli, H.(1);Gregori, D.(1);
(1)University of Padova, Department of Cardiac- Thoracic- Vascular Sciences and Public Health, Padova, Italy;(2)University of Torino, Department of Public Health and Pediatric, Torino, Italy;
N10: The impact of an educational and networking event on nurses caring for Inflammatory Bowel Disease (IBD) paediatric patients receiving biologic therapyECCO'22
Year: 2022
Authors: Gil Zaragozano, E.(1);Wiskin, A.(1);Williams, J.(2);
(1)University Hospitals Bristol and Weston NHS Foundation Trust, Paediatric Gastroenterology, Bristol, United Kingdom;(2)University of the West of England, Faculty of Health and Applied Sciences, Bristol, United Kingdom;